Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma

[1]  Susan M. Chang,et al.  A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[2]  Tai-Gyu Kim,et al.  Potentiation of antiglioma effect with combined temozolomide and interferon-beta. , 2006, Oncology reports.

[3]  Jung-Il Lee,et al.  A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. , 2006, Oncology reports.

[4]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[5]  K. Sugiyama,et al.  [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

[6]  S. Groshen,et al.  Salvage chemotherapy with cyclophosphamide for recurrent temozolomide‐refractory anaplastic astrocytoma , 2006, Cancer.

[7]  I. Ferrer,et al.  Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas , 2005, Clinical Cancer Research.

[8]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[9]  M. Mizuno,et al.  IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. , 2005, Cancer research.

[10]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[11]  James M. Balter,et al.  Imaging Changes after Stereotactic Radiosurgery of Primary and Secondary Malignant Brain Tumors , 2004, Journal of Neuro-Oncology.

[12]  I. Germano,et al.  Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. , 2003, Journal of neurosurgery.

[13]  L Verhey,et al.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. , 2001, AJNR. American journal of neuroradiology.

[14]  Y. Kajita,et al.  Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. , 2001, Neurologia medico-chirurgica.

[15]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  H. Takeuchi,et al.  Analysis of the proliferative potential of tumor cells after stereotactic radiosurgery for recurrent astrocytic tumors , 2000, Neurological research.

[17]  W. Yung,et al.  Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Bucana,et al.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Yung,et al.  Growth Inhibitory Effects of Interferon-β but Not Interferon-α on Human Glioma Cells: Correlation of Receptor Binding, 2′,5′-O1igoadenylate Synthetase and Protein Kinase Activity , 1990 .

[21]  W. Yung,et al.  Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. , 1990, Journal of interferon research.

[22]  M. Moriyama,et al.  Antitumor effect of recombinant murine interferon-beta against mouse malignant glioma. , 1987, Journal of interferon research.